PHAXIAM Therapeutics SA (PHXM)
US29604W2070 - ADR
PHAXIAM Therapeutics SA
NASDAQ:PHXM (3/8/2024, 8:27:22 PM)
After market: 3.1 0 (0%)3.1
-0.02 (-0.64%)
Company Profile
Phaxiam Therapeutics SA is a FR-based company operating in Biotechnology industry. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The firm relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
Company Info
PHAXIAM Therapeutics SA
60 avenue Rockefeller
Lyon AUVERGNE-RHONE-ALPES
P: 33478744438
Employees: 49
Website: https://erytech.com/
PHXM News
2 months ago - Phaxiam Therapeutics S.A.Monthly information related to total number of voting rights and shares composing the share capital – July 1, 2024Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code:...
2 months ago - Phaxiam Therapeutics S.A.Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 1er juillet 2024Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation : Euronext Paris (Compartiment C - Code ISIN : FR001400K4B1 –...
2 months ago - Phaxiam Therapeutics S.A.Results of the Combined General Meeting of 28 June 2024Lyon (France) and Cambridge (MA, US), 28 June 2024 - 5.45 pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company...
2 months ago - Phaxiam Therapeutics S.A.Résultats de l'Assemblée Générale Mixte du 28 juin 2024Lyon (France) et Cambridge (MA, US), le 28 juin 2024 – 17h45 CEST – PHAXIAM Therapeutics (Euronext : PHXM ; FR0011471135) société biopharmaceutique qui...
2 months ago - Phaxiam Therapeutics S.A.PHAXIAM Therapeutics annonce le succès de son augmentation de capital avec maintien du droit préférentiel de souscription de 7,8 M€Lyon (France), le 27 juin 2024 - 17h45 CEST - PHAXIAM Therapeutics (la « Société »), société biopharmaceutique qui développe des traitements innovants...
3 months ago - Phaxiam Therapeutics S.A.Lancement d'une augmentation de capital avec maintien du DPS d’un montant d’environ 10 M€, susceptible d’être porté à environ 11,5 M€ en cas d’exercice intégral de la clause d'extensionNe pas publier, distribuer ou circuler, directement ou indirectement, aux Etats-Unis d’Amérique, au Canada, en Australie, en Afrique du Sud ou au...
PHXM Twits
Here you can normally see the latest stock twits on PHXM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
